Company intelligence / Profile preview

Indivumed

Hamburg, Germany

Ownership: Private
Development stage: Other

Overview

Indivumed has achieved significant milestones in precision oncology by discovering novel cancer targets and developing first-in-class therapeutics. Its patient-centric approach and high-quality tissue samples enable advanced target identification and validation.

Therapeutic areas: Oncology
Modalities: Small moleculesOther modalities
Industry: Biotech

Drug pipeline

8 assets

IN-2402

Preclinical

7 more assets in the full pipeline.

Request access →

Partnerships

Pharmaceutical and biotech companies (undisclosed)

Beyond the preview

Go deeper on Indivumed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Indivumed.

Explore the full profile